Clinical Advances in Ovarian Cancer: Exploring the Expanding Role of PARP Inhibitors in the Treatment Paradigm
To register in advance click here: Link to come.
Gynecologic oncologists, medical oncologists, community oncologists, gynecologists, pharmacists, nurses, nurse practitioners, and other members of the healthcare team who treat patients with women’s cancer.
- Review recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues that may hinder ovarian cancer patients from receiving the current standard of care.
- Appraise landmark and emerging safety and efficacy data with PARP inhibitors in the treatment of ovarian cancer, with a focus on most recent recommendations and rationale for the use of PARP inhibitors in the first-line maintenance setting.
- Analyze the unique toxicity profiles among PARP inhibitor therapies and important considerations for both monitoring and managing adverse events.
- Use an interactive, multi-disciplinary approach to discuss challenging cases regarding the appropriate selection of treatment based on clinical data and guidelines, the use of predictive biomarkers, the management of adverse events, and strategies to mitigate modifiable healthcare disparities in ovarian cancer patients.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from GSK.
To register in advance click here: Link to come.
5 min Welcome and Introductions/Pre-test
15 min Management of Ovarian Cancer: Exploring New Standards of Care
20 min Current Data and Future Prospects of PARP Inhibitors in Ovarian Cancer
15 min Integrating Clinical Data into Clinical Practice—Interactive Case-based Treatment Strategies
5 min Conversations with the Experts/Audience Q&A/Post-test
Floortje J. Backes, MD
Division of Gynecologic Oncology
The Ohio State University
James Cancer Hospital
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Megan May, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Paula Anastasia MN, RN, AOCN–has disclosed that she is on the speakers bureau for Genentech and Seagen and is an advisor or consultant to Merck.
Floortje J. Backes, MD–has disclosed that she receives grants from BeiGene, Eisai, ImmunoGen, and Merck and is an advisor or consultant to Agenus, AstraZeneca, Eisai, GSK, ImmunoGen and Merck.
Judith A. Smith, BS, PharmD., BCOP, CPHQ, FCCP, FISOPP, FHOPA–has disclosed that she receives a salary from VieCure and research support from Plus Therapeutics.
Information to come.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-005-L01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 ICPE
- 1.00 Participation